What is a stock summary page? Click here for an overview.
Business Description
HCW Biologics Inc
NAICS : 541714
SIC : 2834
ISIN : US40423R1059
Description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.08 | |||||
| Equity-to-Asset | -0.38 | |||||
| Debt-to-Equity | -1.28 | |||||
| Debt-to-EBITDA | -0.35 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -10.63 | |||||
| Beneish M-Score | -7.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.9 | |||||
| 3-Year EBITDA Growth Rate | -52.8 | |||||
| 3-Year EPS without NRI Growth Rate | -51.1 | |||||
| 3-Year FCF Growth Rate | -29.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 7.82 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.97 | |||||
| 9-Day RSI | 28.97 | |||||
| 14-Day RSI | 36.5 | |||||
| 3-1 Month Momentum % | -9.48 | |||||
| 6-1 Month Momentum % | -25.64 | |||||
| 12-1 Month Momentum % | -78.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.07 | |||||
| Quick Ratio | 0.07 | |||||
| Cash Ratio | 0.03 | |||||
| Days Sales Outstanding | 93.07 | |||||
| Days Payable | 1833.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8 | |||||
| Shareholder Yield % | -41.35 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 32.41 | |||||
| Operating Margin % | -1023.68 | |||||
| Net Margin % | -1067.82 | |||||
| FCF Margin % | -547.8 | |||||
| ROE % | -626.36 | |||||
| ROA % | -126.17 | |||||
| ROIC % | -144.67 | |||||
| 3-Year ROIIC % | -123.03 | |||||
| ROC (Joel Greenblatt) % | -178.56 | |||||
| ROCE % | -275.44 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.19 | |||||
| EV-to-EBIT | -0.68 | |||||
| EV-to-Forward-EBIT | -2.74 | |||||
| EV-to-EBITDA | -0.7 | |||||
| EV-to-Revenue | 7.2 | |||||
| EV-to-Forward-Revenue | 23.34 | |||||
| EV-to-FCF | -1.31 | |||||
| Price-to-GF-Value | 0.23 | |||||
| Earnings Yield (Greenblatt) % | -147.06 | |||||
| FCF Yield % | -143.31 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:HCWB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
HCW Biologics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3.496 | ||
| EPS (TTM) ($) | -1 | ||
| Beta | 0.37 | ||
| 3-Year Sharpe Ratio | -0.54 | ||
| 3-Year Sortino Ratio | -0.73 | ||
| Volatility % | 83.2 | ||
| 14-Day RSI | 36.5 | ||
| 14-Day ATR ($) | 0.032786 | ||
| 20-Day SMA ($) | 0.33027 | ||
| 12-1 Month Momentum % | -78.27 | ||
| 52-Week Range ($) | 0.2103 - 2.52 | ||
| Shares Outstanding (Mil) | 44.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
HCW Biologics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
HCW Biologics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
HCW Biologics Inc Frequently Asked Questions
What is HCW Biologics Inc(HCWB)'s stock price today?
The current price of HCWB is $0.30. The 52 week high of HCWB is $2.52 and 52 week low is $0.21.
When is next earnings date of HCW Biologics Inc(HCWB)?
The next earnings date of HCW Biologics Inc(HCWB) is 2025-04-01 Est..
Does HCW Biologics Inc(HCWB) pay dividends? If so, how much?
HCW Biologics Inc(HCWB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers